| Primary |
| Hyperparathyroidism Secondary |
54.0% |
| Product Used For Unknown Indication |
19.5% |
| Drug Use For Unknown Indication |
8.6% |
| Renal Failure Chronic |
4.8% |
| Hyperparathyroidism Primary |
3.5% |
| Dialysis |
2.5% |
| Hyperparathyroidism |
1.4% |
| Hypertension |
1.0% |
| Parathyroid Tumour Malignant |
0.8% |
| Hypercalcaemia |
0.7% |
| Secondary Hyperthyroidism |
0.7% |
| Blood Parathyroid Hormone Increased |
0.4% |
| Renal Disorder |
0.4% |
| Convulsion |
0.3% |
| Myocardial Ischaemia |
0.3% |
| Renal Impairment |
0.3% |
| Hyperparathyroidism Tertiary |
0.3% |
| Hyperphosphataemia |
0.3% |
| Nephropathy |
0.3% |
| Blood Calcium Increased |
0.2% |
|
| Death |
17.0% |
| Nausea |
12.2% |
| Vomiting |
11.6% |
| Hospitalisation |
8.2% |
| Blood Parathyroid Hormone Increased |
6.6% |
| Convulsion |
4.1% |
| Rash |
3.9% |
| Hypocalcaemia |
3.2% |
| Weight Decreased |
3.2% |
| Diarrhoea |
3.1% |
| Dysphagia |
3.0% |
| Abdominal Discomfort |
2.9% |
| Gastrointestinal Disorder |
2.9% |
| Muscle Spasms |
2.9% |
| Enteral Nutrition |
2.7% |
| Headache |
2.7% |
| Blood Parathyroid Hormone Decreased |
2.5% |
| Gastrointestinal Tube Insertion |
2.5% |
| Paraesthesia |
2.5% |
| Pruritus |
2.5% |
|
| Secondary |
| Hyperparathyroidism Secondary |
41.4% |
| Renal Failure Chronic |
16.0% |
| Product Used For Unknown Indication |
12.2% |
| Dialysis |
9.7% |
| Hyperparathyroidism Primary |
3.6% |
| Hypertension |
2.8% |
| Peritoneal Dialysis |
2.5% |
| Hypercalcaemia |
1.7% |
| Hyperparathyroidism |
1.7% |
| Anaemia |
1.1% |
| Osteoporosis Postmenopausal |
1.1% |
| Blood Cholesterol Increased |
0.8% |
| Calciphylaxis |
0.8% |
| Drug Use For Unknown Indication |
0.8% |
| Renal Failure |
0.8% |
| Renal Transplant |
0.8% |
| Blood Calcium |
0.6% |
| Blood Calcium Abnormal |
0.6% |
| Blood Calcium Increased |
0.6% |
| Blood Disorder |
0.6% |
|
| Nausea |
11.4% |
| Vomiting |
11.4% |
| Therapeutic Response Decreased |
9.6% |
| Blood Parathyroid Hormone Increased |
8.8% |
| Paraesthesia |
7.9% |
| Blood Calcium Decreased |
4.4% |
| Death |
4.4% |
| Hospitalisation |
4.4% |
| Abdominal Pain |
3.5% |
| Anxiety |
3.5% |
| Blood Parathyroid Hormone Abnormal |
3.5% |
| Diarrhoea |
3.5% |
| Haemoglobin Decreased |
3.5% |
| Malaise |
3.5% |
| Urticaria |
3.5% |
| Abdominal Discomfort |
2.6% |
| Anaphylactic Reaction |
2.6% |
| Blood Calcium Increased |
2.6% |
| Drug Interaction |
2.6% |
| Headache |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
34.6% |
| Product Used For Unknown Indication |
24.7% |
| Nuclear Magnetic Resonance Imaging |
10.8% |
| Angiogram |
3.1% |
| Peritoneal Dialysis |
3.0% |
| Dialysis |
2.9% |
| Hypertension |
2.9% |
| Nuclear Magnetic Resonance Imaging Brain |
2.7% |
| Pain |
2.2% |
| Imaging Procedure |
1.7% |
| Nuclear Magnetic Resonance Imaging Abdominal |
1.4% |
| Fistulogram |
1.3% |
| Hyperparathyroidism Secondary |
1.3% |
| Renal Failure Chronic |
1.3% |
| Prophylaxis |
1.1% |
| Anaemia |
1.1% |
| Haemodialysis |
1.1% |
| Venogram |
1.0% |
| Thrombosis Prophylaxis |
0.9% |
| Hyperphosphataemia |
0.8% |
|
| Vomiting |
17.7% |
| Skin Tightness |
12.4% |
| Therapeutic Response Decreased |
10.5% |
| Nephrogenic Systemic Fibrosis |
7.2% |
| Weight Decreased |
6.2% |
| Death |
5.2% |
| Peritonitis Bacterial |
4.0% |
| Skin Induration |
4.0% |
| Thrombocytopenia |
3.8% |
| Unresponsive To Stimuli |
3.7% |
| Sepsis |
3.0% |
| Xerosis |
2.8% |
| Haemoglobin Decreased |
2.5% |
| Myocardial Infarction |
2.5% |
| Peritonitis |
2.5% |
| Pyrexia |
2.5% |
| Anxiety |
2.3% |
| Skin Hypertrophy |
2.3% |
| Skin Ulcer |
2.3% |
| Tremor |
2.3% |
|
| Interacting |
| Aspergillosis |
50.0% |
| Gastrooesophageal Reflux Disease |
50.0% |
|
| Drug Interaction |
50.0% |
| Inhibitory Drug Interaction |
50.0% |
|
